Compare BYSI & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYSI | NMTC |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 29.2M |
| IPO Year | 2016 | 2010 |
| Metric | BYSI | NMTC |
|---|---|---|
| Price | $0.74 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.90 |
| AVG Volume (30 Days) | 80.2K | ★ 815.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $0.57 | $0.55 |
| 52 Week High | $2.44 | $5.40 |
| Indicator | BYSI | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.65 | 34.12 |
| Support Level | $0.67 | $0.67 |
| Resistance Level | $0.80 | $1.98 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 69.43 | 13.33 |
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.